Clinical Trials Logo

Clinical Trial Summary

This trial studies how well comprehensive lifestyle change works in preventing patients from breast cancer. A program including dietary recommendations, physical activity, stress management and mindfulness training, learning sleep hygiene techniques, and behavioral counseling in addition to social support may help patients who may be at risk for breast cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. Assess the feasibility of a randomized controlled trial involving a mobile, standardized, comprehensive integrative oncology (IO) prevention program. SECONDARY OBJECTIVES: I. Compare group differences over time in biological pathways including: immune function, gut microbiome, endocrine function, insulin and glucose metabolism, inflammation, other cancer-related pathways (from peripheral blood), antioxidant capacity, and nutrient levels. II. Determine whether the IO group has improved patient reported outcomes over time including: quality of life, sleep disturbances, aspects of mental health, and psychosocial measures including: mindfulness, social support, and measures of positive growth. III. Compare group differences over time in dietary patterns, fitness levels, percent body fat, and anthropometrics. OUTLINE: Patients are randomized into 1 of 2 groups. GROUP I: Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks. GROUP II: Patients receive no intervention. After 26 weeks, patients may crossover to Group I. After completion of study, patients are followed up at 26 weeks and 1 year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03448003
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase N/A
Start date April 4, 2019
Completion date August 31, 2025

See also
  Status Clinical Trial Phase
Terminated NCT01842217 - Validation of [18F]FES for Imaging of Brain Estrogen Receptors N/A
Active, not recruiting NCT02760849 - Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations N/A
Withdrawn NCT02734823 - Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor
Completed NCT03505736 - Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
Completed NCT02152943 - Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Phase 1